mBio (Oct 2021)
Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
- Wen Su,
- Sin Fun Sia,
- Aaron J. Schmitz,
- Traci L. Bricker,
- Tyler N. Starr,
- Allison J. Greaney,
- Jackson S. Turner,
- Bassem M. Mohammed,
- Zhuoming Liu,
- Ka Tim Choy,
- Tamarand L. Darling,
- Astha Joshi,
- Ka Man Cheng,
- Alvina Y. L. Wong,
- Houda H. Harastani,
- John M. Nicholls,
- Sean P. J. Whelan,
- Jesse D. Bloom,
- Hui-Ling Yen,
- Ali H. Ellebedy,
- Adrianus C. M. Boon
Affiliations
- Wen Su
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- Sin Fun Sia
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- Aaron J. Schmitz
- Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
- Traci L. Bricker
- Department of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
- Tyler N. Starr
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
- Allison J. Greaney
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
- Jackson S. Turner
- Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
- Bassem M. Mohammed
- Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
- Zhuoming Liu
- Department of Microbiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
- Ka Tim Choy
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- Tamarand L. Darling
- Department of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
- Astha Joshi
- Department of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
- Ka Man Cheng
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- Alvina Y. L. Wong
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- Houda H. Harastani
- Department of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
- John M. Nicholls
- Department of Pathology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
- Sean P. J. Whelan
- ORCiD
- Department of Microbiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
- Jesse D. Bloom
- ORCiD
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
- Hui-Ling Yen
- ORCiD
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- Ali H. Ellebedy
- Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
- Adrianus C. M. Boon
- ORCiD
- Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
- DOI
- https://doi.org/10.1128/mBio.02395-21
- Journal volume & issue
-
Vol. 12,
no. 5
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the main target for neutralizing antibodies. These antibodies can be elicited through immunization or passively transferred as therapeutics in the form of convalescent-phase sera or monoclonal antibodies (MAbs).
